Table 2.
Estimates of treatment coverage and conduct (with 95% CI) in two rounds of MDA in 2016 in Edo state, Nigeria
| Indicator | First round (N = 4,942) | Second round (N = 3,362) |
|---|---|---|
| Took IVM | 31.1% (24.1–38.0%) | 40.0% (31.0–49.0%) |
| Design effect | 5.32 | 5.35 |
| Took IVM, excluding untreated clusters (R1 N = 3,849, R2 N = 3,081) | 45.4% (38.2–52.5%) | 47.2% (39.1–55.3%) |
| Design effect | 4.22 | 4.35 |
| Took ALB (LGAs treating LF only, N = 2,957) | 30.9% (22.2–39.6%) | – |
| Design effect | 5.07 | – |
| Took ALB, excluding untreated clusters (LGAs treating LF only, N = 2,397) | 43.0% (34.3–51.7%) | – |
| Design effect | 3.99 | – |
| Geographic coverage (any treatment in EA) (R1 N = 145, R2 N = 87) | 77% | 90% |
| EAs with coverage more than 80% of total population (R1 N = 145, R2 N = 87) | 12% | 14% |
| Ivermectin coverage in residents of rural EAs (R1 N = 3,356, R2 N = 2,420) | 33.4% (24.2–42.5%) | 45.8% (36.7–54.9%) |
| Ivermectin coverage in residents of urban EAs (R1 N = 1,586, R2 N = 942) | 26.4% (13.0–39.9%) | 34.0% (18.7–49.4%) |
| Received any health education during MDA (ages 5 and above, R1 N = 4,385, R2 N = 3,012) | 33.5% (25.9–41.2%) | 39.1% (30.9–47.3%) |
| Received health education among those treated (R1 N = 1,792, R2 N = 1,510) | 81.6% (74.1–89.1%) | 78.8% (69.5–88.2%) |
| Height measured during MDA | 34.1% (26.4–41.8%) | 36.2% (27.0–45.4%) |
| Height measured among those treated (R1 N = 1,792, R2 N = 1,509) | 82.4% (74.3–90.6%) | 85.5% (78.7–92.2%) |
| Taken IVM before | 34.6% (27.5–41.6%) | 36.3% (26.6–46.0%) |
| Taken ALB before | 33.0% (23.7–42.2%) | – |
ALB = albendazole; EA = enumeration area; IVM = ivermectin; LGA = local government area; MDA = mass drug administration. Italics indicate different denominators than the total study population.